Corvus Pharmaceuticals Inc. (CRVS) Given “Buy” Rating at Credit Suisse Group AG
Credit Suisse Group AG reissued their buy rating on shares of Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) in a research report sent to investors on Tuesday morning. The firm currently has a $25.00 price target on the stock.
Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald set a $23.00 target price on shares of Corvus Pharmaceuticals and gave the company a buy rating in a research note on Saturday, August 6th. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a hold rating to a buy rating and set a $14.00 target price for the company in a research note on Monday, June 20th. Finally, BTIG Research initiated coverage on shares of Corvus Pharmaceuticals in a research note on Thursday, June 2nd. They issued a buy rating for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Corvus Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $21.60.
Corvus Pharmaceuticals (NASDAQ:CRVS) traded up 1.70% during mid-day trading on Tuesday, hitting $16.75. The stock had a trading volume of 5,646 shares. Corvus Pharmaceuticals has a 1-year low of $9.63 and a 1-year high of $16.81. The company has a 50-day moving average price of $14.62 and a 200 day moving average price of $13.92. The company’s market cap is $350.23 million.
A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Advisors LLC raised its stake in Corvus Pharmaceuticals by 437.2% in the second quarter. BlackRock Advisors LLC now owns 456,117 shares of the company’s stock worth $6,504,000 after buying an additional 371,217 shares in the last quarter. Scopia Capital Management LP acquired a new stake in Corvus Pharmaceuticals during the first quarter worth approximately $3,096,000. JPMorgan Chase & Co. acquired a new stake in Corvus Pharmaceuticals during the second quarter worth approximately $2,497,000. Vanguard Group Inc. acquired a new stake in Corvus Pharmaceuticals during the second quarter worth approximately $2,378,000. Finally, HBK Investments L P acquired a new stake in Corvus Pharmaceuticals during the first quarter worth approximately $1,740,000. 82.91% of the stock is owned by hedge funds and other institutional investors.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.